AKORN INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Akorn, Inc. To Contact The Firm
Summary
The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Akorns failure to comply with U.S. Food and Drug Administration ("FDA") data integrity requirements would jeopardize Fresenius SE & Co. KGaAs ("Fresenius") acquisition of Akorn; (2) the Company lacked effective internal controls over financial reporting; and (3) as a result, the Companys financial statements were materially false and misleading.Specifically, on February 26, 2018, Fresenius announced it is investigating alleged breaches of FDA data integrity requirements at Akorn.Fresenius also stated that consummation of the transaction may be affected if the closing conditions under the merger agreement are not met.Related Links NEW YORK, April 3, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akorn, Inc. ("Akorn" or the "Company") (NASDAQ: AKRX ) of the May 7, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.If you invested in Akorn stock or options between March 1, 2017 and February 26, 2018 and would like to discuss your legal rights, click here : www.faruqilaw.com/AKRX .